Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
How can clinicians respond to the alarmingly high rates of maternal mortality in the U.S., and address racial disparities between black and white mothers? This month on Ethics Talk, we discuss how clinicians can improve maternal outcomes.
Harm occurs when race is used as a proxy for characteristics stereotypically ascribed to members of a group, much as the obligatory mention of age is used to indicate the typical patient’s expected health status and vitality.
Medical education must acknowledge the problematic use of race as a biological or epidemiological risk factor in research and the controversy over race.
AMA J Ethics. 2017;19(6):518-527. doi:
10.1001/journalofethics.2017.19.6.peer1-1706.
This process of developing EBM-based guidelines and applying them to clinical care highlights the tension between generating unbiased knowledge based on statistical aggregation and the application of this information to individual patients.
Nisha Quasba joins Ethics Talk to discuss her article, coauthored with Elliot Vice: “What Should Prescribers and Policy Makers Know About US Drug Importation?”